Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesOphthalmology/OptometryBCBS Tennessee Aflibercept Prior Auth | OpenPayer
    Ask Trek AI about this page
    DraftBlue Cross Blue Shield - TennesseePolicy N/A

    Aflibercept Products

    Customize your policy alerts

    Sign up for all blue cross blue shield - tennessee policy alerts

    Know when blue cross blue shield - tennessee releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization and coverage criteria for intravitreal aflibercept products used to treat specified retinal diseases. Coverage applies when the listed indication, prescriber, and clinical response requirements are met; the member’s benefit plan or applicable government program controls if it conflicts with this policy.

    Policy Summary
    PayerBlue Cross Blue Shield - Tennessee
    PolicyAflibercept Products
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateDec 31, 202644d
    Next Review DateN/A
    Key ActionSubmit prior authorization for covered aflibercept products and verify whether step therapy requirements apply.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    8Aflibercept products named in the policy
    12 monthsStandard authorization duration
    5Eylea FDA-approved indication categories
    IntravitrealRoute of administration
    5 doses

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Initial dosing frequency for diabetic macular edema and diabetic retinopathy

    Coverage Criteria

    Diabetic Macular Edema

    Authorization for 12 months may be granted when ALL of the following are met:

    ALL of the following

    • The member has diabetic macular edema.
    • Aflibercept is prescribed by or in consultation with an ophthalmologist.
    • The prescribed product is indicated for diabetic macular edema: Ahzantive, Enzeevu, Eydenzelt, Eylea, Eylea HD, Opuviz, Pavblu, or Yesafili.
    • The member has no exclusions to the prescribed therapy.

    Diabetic Retinopathy

    Authorization for 12 months may be granted when ALL of the following are met:

    ALL of the following

    • The member has diabetic retinopathy.
    • Aflibercept is prescribed by or in consultation with an ophthalmologist.
    • The prescribed product is indicated for diabetic retinopathy: Ahzantive, Enzeevu, Eydenzelt, Eylea, Eylea HD, Opuviz, Pavblu, or Yesafili.
    • The member has no exclusions to the prescribed therapy.

    Neovascular (Wet) Age-Related Macular Degeneration

    Authorization for 12 months may be granted when ALL of the following are met:

    ALL of the following

    • The member has neovascular (wet) age-related macular degeneration.
    • Aflibercept is prescribed by or in consultation with an ophthalmologist.
    • The prescribed product is indicated for neovascular (wet) age-related macular degeneration: Ahzantive, Enzeevu, Eydenzelt, Eylea, Eylea HD, Opuviz, Pavblu, or Yesafili.
    • The member has no exclusions to the prescribed therapy.

    Macular Edema Following Retinal Vein Occlusion

    Authorization for 12 months may be granted when ALL of the following are met:

    ALL of the following

    • The member has macular edema following retinal vein occlusion.
    • Aflibercept is prescribed by or in consultation with an ophthalmologist.
    • The prescribed product is indicated for macular edema following retinal vein occlusion: Ahzantive, Enzeevu, Eydenzelt, Eylea, Eylea HD, Opuviz, Pavblu, or Yesafili.
    • The member has no exclusions to the prescribed therapy.

    Retinopathy of Prematurity

    Authorization for 12 months may be granted when ALL of the following are met:

    ALL of the following

    • The member has retinopathy of prematurity.
    • Aflibercept is prescribed by or in consultation with an ophthalmologist.
    • The prescribed product is Eylea or an indicated aflibercept biosimilar.
    • The member has no exclusions to the prescribed therapy.

    Continuation Therapy

    Authorization for 12 months may be granted for continued treatment when ALL of the following are met:

    ALL of the following

    • The member is requesting reauthorization for an indication listed in the coverage criteria section.
    • The member has demonstrated a positive clinical response to therapy.

      Examples include improvement or maintenance in best corrected visual acuity (BCVA) or visual field, or a reduction in the rate of vision decline or the risk of more severe vision loss.

    Aflibercept Product Dosing Regimens

    The following product-specific aflibercept regimens are administered intravitreally unless otherwise noted:

    Applicable product and indication regimen

    • Opuviz (aflibercept-yszy) — Neovascular (wet) age-related macular degeneration

      • Initial: 2 mg per affected eye every 4 weeks for the first 3 months.
      • Maintenance: 2 mg per affected eye every 4 weeks (approximately every 25 days; monthly).
    • Pavblu (aflibercept-ayyh) — Diabetic macular edema

      • Initial: 2 mg per affected eye every 4 weeks for 5 doses.
      • Maintenance: 2 mg per affected eye every 4 weeks (approximately every 25 days; monthly).

    FDA-approved indications are covered only when the applicable approval criteria are met and the member has no exclusions to the prescribed therapy. All other indications are considered experimental/investigational and not medically necessary.

    Aflibercept use for indications outside those listed in this policy is not medically necessary.

    Authorization and Documentation Requirements

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for coverage of the listed aflibercept products when used for a covered indication. Approval is subject to the applicable coverage criteria and any plan requirements.

    • Covered products include Eylea, Eylea HD, Ahzantive (aflibercept-mrbb), Enzeevu (aflibercept-abzv), Eydenzelt (aflibercept-boav), Opuviz (aflibercept-yszy), Pavblu (aflibercept-ayyh), and Yesafili (aflibercept-jbvf).
    Note

    Initial Authorization Duration

    Initial authorization may be granted for 12 months when the member is being treated for one of the listed covered indications and all applicable approval criteria are met.

    • Diabetic macular edema
    • Diabetic retinopathy
    • Neovascular (wet) age-related macular degeneration
    • Macular edema following retinal vein occlusion

    Therapy Background

    Aflibercept is an intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy used to treat retinal vascular and macular disorders, including diabetic macular edema, diabetic retinopathy, neovascular (wet) age-related macular degeneration, macular edema following retinal vein occlusion, and retinopathy of prematurity for applicable products.

    Key Terms

    Neovascular (Wet) Age-Related Macular Degeneration
    DefinitionAge-related macular degeneration involving abnormal blood vessel growth associated with the wet form of the disease.
    BCVA
    MeaningBest corrected visual acuity.
    Continuation-therapy roleA positive clinical response may be demonstrated by improvement or maintenance in BCVA.
    Policy Summary
    PayerBlue Cross Blue Shield - Tennessee
    PolicyAflibercept Products
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateDec 31, 202644d
    Next Review DateN/A
    Key ActionSubmit prior authorization for covered aflibercept products and verify whether step therapy requirements apply.
    SourceLink
    On This Page
    Coverage CriteriaAuthorization and Documentation RequirementsTherapy BackgroundKey Terms
  1. Pavblu (aflibercept-ayyh) — Diabetic retinopathy

    • Initial: 2 mg per affected eye every 4 weeks for 5 doses.
    • Maintenance: 2 mg per affected eye every 4 weeks (approximately every 25 days; monthly).
  2. Pavblu (aflibercept-ayyh) — Macular edema following retinal vein occlusion

    • 2 mg per affected eye every 4 weeks (approximately every 25 days; monthly).
  3. Pavblu (aflibercept-ayyh) — Neovascular (wet) age-related macular degeneration

    • Initial: 2 mg per affected eye every 4 weeks for the first 3 months.
    • Maintenance: 2 mg per affected eye every 4 weeks (approximately every 25 days; monthly).
  4. Yesafili (aflibercept-jbyf) — Diabetic macular edema

    • Initial: 2 mg per affected eye every 4 weeks for 5 doses.
    • Maintenance: 2 mg per affected eye every 4 weeks (approximately every 25 days; monthly).
  5. Yesafili (aflibercept-jbyf) — Diabetic retinopathy

    • Initial: 2 mg per affected eye every 4 weeks for 5 doses.
    • Maintenance: 2 mg per affected eye every 4 weeks (approximately every 25 days; monthly).
  6. Yesafili (aflibercept-jbyf) — Macular edema following retinal vein occlusion

    • 2 mg per affected eye every 4 weeks (approximately every 25 days; monthly).
  7. Yesafili (aflibercept-jbyf) — Neovascular (wet) age-related macular degeneration

    • Initial: 2 mg per affected eye every 4 weeks for the first 3 months.
    • Maintenance: 2 mg per affected eye every 4 weeks (approximately every 25 days; monthly).
  8. Retinopathy of prematurity for Eylea and biosimilars only
  9. Step Therapy

    Check External Step Therapy Requirements

    Some aflibercept products may require step therapy before approval. Review and apply the applicable Step Therapy Requirements for Provider Administered Specialty Medications.

    • Step Therapy Requirements for Provider Administered Specialty Medications: https://www.bcbst.com/docs/providers/Comm_BC_PAD_Step_Therapy_Guide.pdf
    Documentation Required

    Ophthalmologist Involvement Required

    The medication must be prescribed by or in consultation with an ophthalmologist. Document the ophthalmologist's involvement with the request.

    Documentation Required

    Document Positive Clinical Response

    Reauthorization may be granted for 12 months when the member has demonstrated a positive clinical response to therapy.

    • Examples include improvement or maintenance in best corrected visual acuity (BCVA) or visual field, or a reduction in the rate of vision decline or the risk of more severe vision loss.
    Denial Risk

    Unlisted Indications Not Covered

    Aflibercept use for indications other than the listed FDA-approved or compendial indications is considered experimental/investigational and not medically necessary.

    Denial Risk

    All Criteria and No Exclusions Required

    Coverage is available only when all applicable approval criteria are met and the member has no exclusions to the prescribed therapy.

    • Eylea is covered for diabetic macular edema, diabetic retinopathy, neovascular (wet) age-related macular degeneration, macular edema following retinal vein occlusion, and retinopathy of prematurity.
    • Ahzantive, Enzeevu, Eydenzelt, Eylea HD, Opuviz, Pavblu, and Yesafili are covered for diabetic macular edema, diabetic retinopathy, neovascular (wet) age-related macular degeneration, and macular edema following retinal vein occlusion.